David A. Stamler, M.D.
Chief Scientific Officer and Head of Development

Dr. Stamler joined Prestwick as our Chief Scientific Officer and Head of Development in June, 2005. Before joining Prestwick, Dr. Stamler had 12 years of experience within the pharmaceutical industry. From 2003 to 2005 he was the Senior Global Project Leader for Central Nervous System (CNS) Diseases for Fujisawa Pharmaceutical Company, where he led global development activities for two drugs to treat Alzheimer's Disease and a drug for acute stroke. From 2003 to 2005, he also served as the Vice President of Research and Development, Medical Sciences for its U.S. subsidiary, Fujisawa Healthcare, Inc., chairing the Protocol Review Committee, and serving on the Global Development Investment Committee. From 1997 to 2003, Dr. Stamler held positions of increasing responsibility for the Fujisawa Research Institute of America, Inc. He began his tenure as Medical Director and culminating as Vice President, a position he held from 2000 to 2003 and also chairing the CNS Therapeutic Area Committee. At Abbott Laboratories, Dr. Stamler was the Director of Clinical Research, Pharmaceutical Products for the International Division from 1995 to 1997. Key activities during this period included medical oversight of European registration for the HIV protease inhibitor ritonavir, strategic planning with sales and marketing to defend existing businesses, oversight of clinical research at the country level and new product evaluation for in-licensing. From 1993 to 1995, Dr. Stamler was Associate Medical Director, Anti-infectives, with responsibility for Phase 1-4 trials in respiratory infection and H. pylori-associated gastrointestinal infection.

Dr. Stamler received his B.A. and M.D. from the University of Chicago. He completed his Residency in Internal Medicine at Temple University Hospital as well as Fellowships in Infectious Diseases and Clinical Microbiology at the University of Pennsylvania. He is board certified in Internal Medicine and Infectious Diseases.

He is a founding member of the American Society of Experimental NeuroTherapeutics (ASENT), a member of the American Academy of Neurology and the American College of Physicians. He has authored publications in peer-reviewed scientific journals for CNS, gastrointestinal, respiratory and inflammatory diseases.